US2002045603A1PendingUtilityA1

Method of inhibiting membrane-type matrix metalloproteinase

45
Assignee: UNIV NEW YORK STATE RES FOUNDPriority: Mar 31, 1998Filed: May 14, 2001Published: Apr 18, 2002
Est. expiryMar 31, 2018(expired)· nominal 20-yr term from priority
Inventors:Lorne M. GolubHsi-Ming LeeTimo SorsaOlli TeronenTuula Salo
A61P 35/00A61P 43/00A61K 31/65
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention is a method of inhibiting the activity of membrane-type matrix metalloproteinase (MT-MMP) in biological systems. Accordingly, the invention permits the treatment of medical conditions in mammals that are characterized by MT-MMP activity, and especially those conditions characterized by excessive MT-MMP activity. The method employs a tetracycline compound, preferably a non-antimicrobial tetracycline, and more preferably 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3) or 6-α-deoxy-5-hydroxy-4-de(dimethylamino)tetracycline (CMT-8) to inhibit the MT-MMP activity.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of inhibiting membrane-type matrix metalloproteinase activity in a biological system, comprising administering to the system in need thereof an MT-MMP-inhibitory amount of a tetracycline compound.  
     
     
         2 . A method according to  claim 1 , wherein the tetracycline compound is administered in an amount that has substantially no antimicrobial activity.  
     
     
         3 . A method according to  claim 1 , wherein the biological system has excessive MT-MMP activity, and the method comprises administering to the system an amount of the tetracycline compound sufficient to inhibit the excessive MT-MMP activity.  
     
     
         4 . A method according to  claim 1 , wherein the biological system comprises cultured mammalian cells.  
     
     
         5 . A method according to  claim 4 , wherein the mammalian cells comprise tumor cells, osteoclasts, or fibroblasts.  
     
     
         6 . A method according to  claim 1 , wherein the biological system is a mammal.  
     
     
         7 . A method according to  claim 5 , wherein the mammal has a condition characterized by excessive MT-MMP activity.  
     
     
         8 . A method according to  claim 5 , wherein the mammal has a cancer.  
     
     
         9 . A method according to  claim 8 , wherein the cancer is a carcinoma, fibrosarcoma, or osteosarcoma.  
     
     
         10 . A method according to  claim 5 , wherein the mammal has a condition characterized by excessive osteoclast activity.  
     
     
         11 . A method of inhibiting the invasive potential of carcinoma cells, fibrosarcoma cells, or osteosarcoma cells, comprising contacting the cells with an invasion-inhibitory amount of a tetracycline compound.

Join the waitlist — get patent alerts

Track US2002045603A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.